Business
Gossamer Bio Announces First Quarter 2026 Financial Results and Provides Business Update
SAN DIEGO, May 18, 2026--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the first quarter ended March 31, 2026, and provided a business update. Gossamer Bio and the Chiesi Group are jointly developing seralutinib under a glob
About this update from Gossamer Bio, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":239,"url":"https://media.zenfs.com/en/business-wire.com/d677d23c01499c9743704e3fec93176d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/TTk5kSv2wILF.80Id.4IlA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ3OA--/https://media.zenfs.com/en/business-wire.com/d677d23c01499c9743704e3fec93176d","width":480,"height":239},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/RW1tOeOhJ9mkcNCR_EfGnA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTMxOQ--/https://media.zenfs.com/en/business-wire.com/d677d23c01499c9743704e3fec93176d","width":480,"height":239}},"lazy":false},{"type":"text","content":"- FDA Confirms In-Person Pre-NDA Type B Meeting in Mid-June -","length":61,"tagName":"p","attribs":{}},{"type":"text","content":"- Positive PROSERA CT FRI Results Demonstrated Multiple Statistically Significant Treatment Effects, Including Novel Signals Correlated with Clinical Outcomes -","length":160,"tagName":"p","attribs":{}},{"type":"text","content":"- Gossamer Announces Commencement of Exchange Offer and Consent Solicitation for Outstanding 5.00% Convertible Senior Notes Due 2027 -","length":134,"tagName":"p","attribs":{}},{"type":"text","content":"- Cash, cash equivalents and marketable securities totaled $99 million as of March 31 -","length":87,"tagName":"p","attribs":{}},{"type":"text","content":"SAN DIEGO, May 18, 2026--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the first quarter ended March 31, 2026, and provided a business update. Gossamer Bio and the Chiesi Group are jointly developing seralutinib under a global collaboration agreement.","length":544,"tagName":"p"},{"type":"text","content":""We are executing across multiple fronts at Gossamer," said Faheem Hasnain, Chairman, Co-Founder, and CEO of Gossamer Bio. "We have secured an in-person Pre-NDA Type B meeting with the FDA, reflecting our conviction in both the breadth of the PROSERA dataset and in the totality of evidence supporting seralutinib. S...